Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 154
Summary
- Conditions
- Breast Cancer
- Colorectal Cancer
- Hepatocellular Cancer
- Lung Cancer
- Pancreatic Cancer
- Renal Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02947165
- Collaborators
- Not Provided
- Investigators
- Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals